Clinical Trial Update: Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of lenalidomide and azacitidine for relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Revlimid (lenalidomide)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Hackensack Meridian Health | Conditions: Chronic Lymphocytic Leukemia(CLL), Small Lymphocytic Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2022-07-20